ライフサイエンスコーパス: breast mass

1 seroma and 7 of 83 (8%) with an isolated new breast mass.

2 are required to accurately evaluate a solid breast mass.

3 e in the preoperative triage of women with a breast mass.

4 ction with the B-mode to classify suspicious breast masses.

5 roved classification of benign and malignant breast masses.

6 diabetic mastopathy presented with palpable breast masses.

7 ng cyclosporin A therapy had newly developed breast masses.

8 benign components of small tissue samples of breast masses.

9 nce in differentiating benign from malignant breast masses.

10 uently validated in in vivo studies on human breast masses.

11 formance of ultrasound for classification of breast masses.

12 lone in differentiating benign and malignant breast masses.

13 neck mass (4.2%), undescended testes (1.9%), breast mass (1.2%), club foot (1%), hypospadias (0.6%),

14 ng Reporting and Data System category 4 or 5 breast masses (35 invasive cancers, 74 benign) from 2013

15 e range, 25-86 years) with 101 biopsy-proved breast masses (45 benign, 56 malignant).

16 approach to the detection and management of breast masses and focal asymmetries.

17 isease with expected avidity in two separate breast masses and multiple conglomerated 1-2 cm level I

18 onclusion OA/US increases the specificity of breast mass assessment compared with the device internal

19 8)Ga-FAPI PET/CT excels in detecting primary breast masses, axillary lymph nodes, and distant metasta

20 differentiation between malignant and benign breast masses, but it should be used in conjunction with

21 nclusion AI applied to portable US images of breast masses can accurately identify malignancies.

22 n this paper, we introduce the final step of breast mass classification and diagnosis using a stacked

23 f ten index surgically treatable conditions (breast mass, cleft lip/palate, club foot, hernia or hydr

24 e three-compartment breast image analysis of breast masses combined with mammography radiomics has th

25 Therefore, we hypothesized that malignant breast masses could be imaged and quantitated externally

26 a computer-aided detection (CAD) system for breast mass detection on digital breast tomosynthesis (D

27 Ultrasound-guided core needle biopsy of the breast mass diagnoses an invasive ductal carcinoma, poor

28 ls and Methods Lactating women with palpable breast masses evaluated at targeted US over a 17-year pe

29 In this study 46 women had their breast mass excised.

30 rformed HMI scans in 10 female subjects with breast masses: five benign and five malignant masses.

31 observers could accurately classify palpable breast masses for triage in a low-resource setting.

32 ethod for biopsy of radiopharmaceutical-avid breast masses guided by data from PET and SPECT scanners

33 Patients with a breast mass had worse OS and progression-free survival (

34 med in 151 consecutive solitary, nonpalpable breast masses in 151 women (age range, 23-80 years) by u

35 The US features of 31 breast masses in 23 patients were reviewed.

36 Three hundred forty-eight consecutive breast masses in 328 women who underwent image-guided or

37 Of 853 breast masses in which LCNB was performed, 38 (4%) revea

38 sk of classifying the detected and segmented breast masses into malignant or benign, and diagnosing t

39 e safety and performance of MSOT for imaging breast masses intraoperatively.

40 esized that the PBMC response to a malignant breast mass involves elevated production of HSP70 and a

41 (age range, 17-87 years), which yielded 803 breast mass lesions (296 malignant, 507 benign).

42 Breast masses (n = 35) showed significantly higher early

43 for injuries or wounds, hernias, hydroceles, breast mass, neck mass, obstetric fistula, undescended t

44 itions (injuries/wounds, hernias/hydroceles, breast masses, neck masses, obstetric fistulas, undescen

45 hysical examination reveals neither palpable breast mass nor axillary lymphadenopathy.

46 racy in distinguishing malignant from benign breast masses on 3D US volumetric images.

47 atients aged 18 years or older with palpable breast masses presenting to the FNAB Clinic at Muhimbili

48 l lymph node (SNL) mapping in a woman with a breast mass presents an unacceptable risk to her fetus.

49 ion and morphology of blood vessels in solid breast masses seen at power Doppler US is a potentially

50 y does not help determine whether a palpable breast mass should be biopsied and should not affect the

51 Material/Seventy-nine breast masses that were classified as BI-RADS category 3

52 painless breast lump and no prior history of breast masses, trauma, or surgery.

53 total of 125 female patients with suspicious breast masses underwent MRI with the AP and the FDP.

54 Nineteen patients with posterior breast masses underwent three-dimensional, gradient-echo

55 Thirty-four women with breast masses underwent US-guided biopsy with an 11-gaug

56 A total of 1972 women (with a total of 2055 breast masses) underwent prebiopsy optoacoustic US in a

57 asks on small datasets-thyroid nodules (US), breast masses (US), anterior cruciate ligament injuries

58 independent readers to benign and malignant breast masses using OA/US versus US alone.

59 US strain imaging of 403 breast masses was performed.

60 ces between women with a benign or malignant breast mass were determined.

61 A total of 452 solid breast masses were evaluated in a surgical breast clinic

62 Seventy-three consecutive biopsies of breast masses were performed by using a 14-gauge handhel

63 Results: All breast masses were successfully imaged as cancers using

64 Eighty-six solid breast masses, which were subsequently sampled for biops

65 Percutaneous biopsy of a nonpalpable breast mass with either US or stereotactic guidance is l

66 After removal of all US evidence of breast masses with a VAB device, there was a substantial

67 ents with Carney complex often have multiple breast masses with variable imaging appearances that pro

68 nguishing between benign and malignant solid breast masses, with biopsy results as the reference stan

69 the cancerous probability of any suspicious breast mass without any sample excision.